NovaBridge Biosciences (ADR) (NBP)
Develops asset-focused oncology and retinal-disease programs through dedicated therapeutic subsidiaries.
$1.79
Pre-market+0.01 (+0.56%)
At close$1.78(+2.89%)
Something off on this page? Send us feedback.
Breakdown13F · 13D/G · Form 4
50.12M ADS as of Aug 21, 2026 · holders as of their latest filing
The share count has not been confirmed by a second filing; stakes use it as it stands.
Some positions are filed in underlying shares, not receipts; the ratio is unknown, so no percentage.
Institutions13F
No 13F holders on record.
Ownership statements13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| Everest Medicines Limited | 16.10% | 42.52M | 13D | Aug 5, 2025 ↗ |
| Wei Fuincl. CBC Investment I-Mab Limited, IBC Investment Seven Limited +9 more | 11.50% | 30.50M | 13D | Feb 3, 2026 ↗ |
Insider tradesForm 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Aug 31, 2026 | Cong Claire Xuofficer: EVP, Clinical Development | Sale | 3,282 | $0.7900 | 304,201 |
| Jul 6, 2026 | Cong Claire Xuofficer: SVP, Clinical Development | Sale | 4,485 | $0.8900 | 298,101 |
| Jun 18, 2026 | Phillip Andrew Dennisofficer: Chief Medical Officer | Sale | 8,494 | $0.6600 | 157,941 |
| Jun 1, 2026 | Cong Claire Xuofficer: SVP, Clinical Development | Sale | 3,494 | $3.94 | 290,154 |
| May 14, 2026 | Sean Wuxiong Caodirector, officer: See Remarks | Sale | 21,399 | $1.99 | 35,073 |
| Apr 24, 2026 | Mark Arnold Haglerofficer: See Remarks | Purchase | 230,000 | $2.51 | 230,000 |
CongressHouse and Senate disclosures
Not reported.